Glenmark Pharmaceuticals revealed that its anti-diarrhea drug has been approved by FDA.

Crofelemer has been developed by Glenmark who acquired the license to manufacture it from Napo Pharmaceuticals who had initially discovered the major compound used in the drug.
“This is a significant approval milestone and will enable the first NCE launch by Glenmark across emerging markets. Most importantly, this is a significant step forward in addressing the unmet medical need of people with HIV/AIDS on anti-retovirals who experience non-infectious diarrhea, which often can lead to reduced treatment compliance. This will also help us accelerate filing across countries and also propel our development in additional diarrhea indications including the acute indications”, Genlmark’s chairman, Glenn Saldanha said.
Source-Medindia